Clinical trials: Chromaffin-tissue Derived Tumors
Chromaffin-tissue Derived Tumors
Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Context. Nuclear imaging plays a central role in management of chromaffin-tissue derived tumors because tumor cells exhibit peptide receptors and proteins involved in metabolism that can be targeted with specific…
- Trial name
- NCT00875407
- Testing
- Scintigraphy in 123I-IBZM
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique Hopitaux De Marseille